GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teva Pharmaceutical Industries Ltd (NYSE:TEVA) » Definitions » Degree of Financial Leverage

Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) Degree of Financial Leverage : 0.65 (As of Dec. 2023)


View and export this data going back to 1990. Start your Free Trial

What is Teva Pharmaceutical Industries Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Teva Pharmaceutical Industries's Degree of Financial Leverage for the quarter that ended in Dec. 2023 was 0.65. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Teva Pharmaceutical Industries's Degree of Financial Leverage or its related term are showing as below:

TEVA's Degree of Financial Leverage is ranked better than
67.82% of 1041 companies
in the Drug Manufacturers industry
Industry Median: 0.98 vs TEVA: 0.65

Teva Pharmaceutical Industries Degree of Financial Leverage Historical Data

The historical data trend for Teva Pharmaceutical Industries's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teva Pharmaceutical Industries Degree of Financial Leverage Chart

Teva Pharmaceutical Industries Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Degree of Financial Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.83 0.43 0.77 2.78 0.65

Teva Pharmaceutical Industries Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.78 -0.36 -124.64 -6.20 0.65

Competitive Comparison of Teva Pharmaceutical Industries's Degree of Financial Leverage

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teva Pharmaceutical Industries's Degree of Financial Leverage Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's Degree of Financial Leverage falls into.



Teva Pharmaceutical Industries Degree of Financial Leverage Calculation

Teva Pharmaceutical Industries's Degree of Financial Leverage for the quarter that ended in Dec. 2023 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -0.5 (Dec. 2023) / -2.2 (Dec. 2022) - 1 )/( 405 (Dec. 2023) / -2233 (Dec. 2022) - 1 )
=-0.7727/-1.1814
=0.65***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Teva Pharmaceutical Industries  (NYSE:TEVA) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Teva Pharmaceutical Industries Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) Business Description

Address
124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.
Executives
Dov Bergwerk officer: Acting Chief Legal Officer C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Vikki L Conway officer: See "Remarks" C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Varda Shalev director MATAM PARK, BUILDING #5, HAIFA L3 3508409
Eliyahu Sharon Kalif officer: EVP, Chief Financial Officer C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Amir Weiss officer: Chief Accounting Officer C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Angus Grant officer: EVP, Business Development C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Eric A Hughes officer: See "Remarks" C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Sven Dethlefs officer: EVP Global Marketing&Portfolio 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Eric Drape officer: Executive VP Global Operations C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
David Matthew Stark officer: Exec. VP Chief Legal Officer 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Richard Daniell officer: Exec. VP, European Commercial 5 BASEL STREET, PO BOX 3190, PETACH TIKVA L3 4951033
Richard D Francis officer: President and CEO IM LANGACHER 44, GREIFENSEE V8 8606
Hafrun Fridriksdottir officer: Executive VP, Global R&D 400 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Eli Shani officer: EVP,Global Marketing&Portfolio C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Tal Zvi Zaks director C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX